{"name":"Telix Pharmaceuticals (Innovations) Pty Ltd","slug":"telix-pharmaceuticals-innovations-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","indication":"Prostate cancer","status":"phase_1"},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","indication":"Prostate cancer","status":"phase_1"},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","indication":"Neuroendocrine tumors","status":"phase_1"}]}],"pipeline":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","phase":"phase_1","mechanism":"A radioligand targeting somatostatin receptors","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","phase":"phase_1","mechanism":"Iodine-131 labelled peptide for targeted radionuclide therapy","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","phase":"phase_2","mechanism":"177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","phase":"phase_3","mechanism":"177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","phase":"phase_1","mechanism":"Somatostatin receptor targeting","indications":["Neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOWkltMnlydVgyQUltbndLNGszMWFqUlJMSTU5UE9teWZCTWZrQjIxNHc1YTd4V3dfY29RNEVaazB0LXNGRkx3VzhlYzdRNFJKaVd3a09qZF9LY2FRYTV6aTlianhEXzhlN2s2RURaYTBkbUpzUkhCWlIyZXlRSmRfTmcwUlpIYUxWbVZyYVJDNUJnODZXb2hfSGZNTGV1QURTYl9ka0pMTnBYTjY3MHp2Yw?oc=5","date":"2026-03-28","type":"pipeline","source":"kalkinemedia.com","summary":"Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift - kalkinemedia.com","headline":"Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPV2poMTJ5ZDJpamdFR1gtbmF1bzlaSXFOUi1Qb0ZvYXM2Qjk3N09xYTNGSFVFbkdiX2JsN1hsZGc0NURma2F2VmJUMVRuWWNpcldzVG5BUXAtcDVCRWtYQVlOU25kSjNUdmFFQkYzcUpBMU5uaVdybGRzZldBbEhRalBKNWlkdVQtb3V5WDBHakpVWUExUnFudFRnZjdiUQ?oc=5","date":"2026-03-24","type":"pipeline","source":"kalkinemedia.com","summary":"Telix Pharma Gains Traction on Radiopharma Progress - kalkinemedia.com","headline":"Telix Pharma Gains Traction on Radiopharma Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdXVQcUVUMXdBa0lPYlk1dTZiTFJpUXhfc1VKek9PTE0zcEFUeDRoV1VjTFFIRkJwWEZIQTU4VU5wc0t1RW95QjVfQy1LWS1teU9CcU94Z2tTcmhXYjY1cjRiMXQwN1A1S084bS1zZFNCMW5Jam11OFR0ZEJpQVloZ2ZCZWhhQ0p6REZWblZ6RUt6U2dyY3ZoNW9jM01LX1ZpWUo2QzlLM09DaDhTaldLTEp3NDlwdWR1U2F1UTYxNmE?oc=5","date":"2026-03-18","type":"pipeline","source":"AD HOC NEWS","summary":"Telix Pharmaceuticals Ltd Stock (ISIN: AU000000TLX2) Surges 8% on Radiopharma Momentum Amid Analyst - AD HOC NEWS","headline":"Telix Pharmaceuticals Ltd Stock (ISIN: AU000000TLX2) Surges 8% on Radiopharma Momentum Amid Analyst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPM3cwM2hvb3BZYnU2QmpzbWlSMkk3S1pBNklNaUQ3VTVfVWVtaHVVeGhYZUQ3WElKaGRfNUI0RzZnYjRoYXJpWjBLXzhCUTZVTlhURUlsVG1VVXFvZUs5MTZKR0N5b2Z6cVg4QlF4Y1cwdG5LSmFXZTZoUVJWT1k2MXB1eUZWSlJuVFdsV0NzWHFwQTNCM1k3YmROTmFNd0xkQ2IyQi1femhPanc?oc=5","date":"2025-12-22","type":"regulatory","source":"The Motley Fool Australia","summary":"Telix Pharmaceuticals in focus with China trial success and FDA updates - The Motley Fool Australia","headline":"Telix Pharmaceuticals in focus with China trial success and FDA updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZm9SQ2RqRHNrRnItYk1NSnpXVHVXaGFkckg3cHRHMTJSNmt4RE5wSkZlemthME82R0F3c3diR0tqRmhXRVVIdklxOVg4VGFjd0dUQmdaZy13S00zUEx6SjRubGFCS18wcjBLLTdDZ3VSTXFndFlfOHA3aDk3RnhxWVZXRElXVVc0TDVkZllrQzYtNm9YbzBuN1B3a2lXTXc4Y2xzazFCVDVScGhmeHFRdm5NaWJiUDhi?oc=5","date":"2025-11-21","type":"pipeline","source":"BioSpectrum Asia","summary":"Telix Pharma opens first cyclotron facility in Asia Pacific region - BioSpectrum Asia","headline":"Telix Pharma opens first cyclotron facility in Asia Pacific region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPVFR4ZjVBMy1iODdFNWdUa1N2TlFMdWRCLTJ0R0xKUVlvU1ZoQXJ5ajFDVW56dkZVODIzWHc3R29ZMFUzcDVyLV8zZFhGNTdhR0dITkIzQ1NIak1tYUdrQ1Z4N2JET1lDSjFTT1lUT01NU2EyS3NTSHpxYnd1V1BrQ1YzSXZmZUEtNFpWWnB3S1BwdHJ5UDZHUDFiamgxR0JXOXhGbndNMUlOZmNwMnNGME53M1VCN250d1JFaDdUWVFzU2UwaWt1aTBWTktCbnVONG9MRA?oc=5","date":"2025-10-22","type":"trial","source":"GlobeNewswire","summary":"Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain - GlobeNewswire","headline":"Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxONXZxZ1MwWnFYSldwakxiQzRrVlhhdUJWcE15aGZUclZiS0IxaVBYcHRKRHRiM2hfZjlySWtQb0tIM2hCdzFKc0VUeU9WSUFuRnhvb2FGR0VSOWNQT2tFUGtqSVBJaXJpVlVOTVBKWmN1dFhnTFBiTVZzaUZSN0NzV0lUcUppNFFpdWo5eTFGZUpTSjBfdWVLY2ZEVGpDNDlFQ25OcDc4TUxxSk5ZOEU0WXBKUzVLY1FJazR0T19HZU5xRjBpYXM4NWhKSQ?oc=5","date":"2025-10-09","type":"pipeline","source":"Biotech Dispatch","summary":"AusBiotech unveils international conference program for Australia’s biggest week in biotech - Biotech Dispatch","headline":"AusBiotech unveils international conference program for Australia’s biggest week in biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQdndISjlmUWptZkhTekoyQVd3UWwzSUdWUW85Qkp5Q2FTM0cwTlJ6RUJYel9OOXVjQWFNZjdqNXIzRDRMd0d2Y0JmcWhNcXpSaGFpX3J4d0IzYy1rVWlQSTU5Rm13VHhkdndmWHFUd0Z1enZnTGpJUExaSXhtOFUzUEZOM0NkZFVudnVkNVRiOHZRa3gwVHdXV19OdzcyN05EM3I5ZXdVUC11WDFlN3VUNVdhLTBNVXlmM0E?oc=5","date":"2025-09-26","type":"pipeline","source":"AFR","summary":"CSL, Telix and other pharma groups rush to calm investor fears over Donald Trump’s tariff hit - AFR","headline":"CSL, Telix and other pharma groups rush to calm investor fears over Donald Trump’s tariff hit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR0twSHktVk9leUVGV0wyVHBycDh6VjFabXRJQnhQSkNzamJOWjBoSFVmSHltYUpTcXV0dXJ6TEhtVFNhdlNIMGwwYlBmbFFtT1FBX1lkV1VuTWVqQ3ZXMjZKaXJ3V1Y0TXdwMk5kWU0ya0Z3RlNPTUN2MVN4akVSRVgyTFBPdERVN0tBc3B3Wk52MEx1aGZvTU9tVVNOanBwZUtjNDFmVXJ4OG1uT1R4bnd3djFERXB2WVdZ?oc=5","date":"2025-05-26","type":"pipeline","source":"Forbes Australia","summary":"Australian startups take on big pharma with precision cancer breakthroughs - Forbes Australia","headline":"Australian startups take on big pharma with precision cancer breakthroughs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRXNiRjBUd3VlaXBoWGlueUJXTFBNWFlsd0Z5ZENkRm5valpHZFowNjIxemlfQ0FJTlltQmdkRDNLLTNfdVlTV1hPU2xHOUZGTUxfZTFZSUQtWE9DTDd3YUp4UWhZd09Ya3JSd2NqQzFJOWxJcVF4NHRCSFlHOHY5bDdpQmhYWnpueTFtLXJlTWpYaEFTam8yU3pHc0Jyak5BS09WN2lzTklHdw?oc=5","date":"2025-05-13","type":"pipeline","source":"Australian Broadcasting Corporation","summary":"Trump's pharmaceutical 'tariff wall' is coming — is Australia ready? - Australian Broadcasting Corporation","headline":"Trump's pharmaceutical 'tariff wall' is coming — is Australia ready?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNcGhTMXcxMEpOc0lDeXlBUzVUdWd3eGpaNlM1N0tzR0lmN0duRmJPYjM4V3JBZmFFcGl2eFJhLVF5VHNXTmplQ19IcjlmRjloQTNJNGJOb2pjamVlcUtpWHViRjdEYXhGd3ZqTl9aX3hPVy1DMVJ1X2IzQk5HQkNqTW1vSmd6WmoxRW1aUE9YZVNXMXIydXhzejhDY3NZM0VtMWhSdWxsN19TTkNJQWdaNW5oN2M5RXhDYnJWWm5BRXdGUFFoUkpqWF9Lb1BrUzNteW5NSGpVMzBSSWtxalFCT0VVRTBaQQ?oc=5","date":"2025-01-13","type":"deal","source":"radiologybusiness.com","summary":"Telix Pharmaceuticals to acquire portfolio of imaging-related assets for up to $185M - radiologybusiness.com","headline":"Telix Pharmaceuticals to acquire portfolio of imaging-related assets for up to $185M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQUDR3WkZSaFUteVRZOXdNSHpfX1F5ZDRucHFUY3hpU1l5dDBqcnJ4MExwOEtUSkNVV1J4TEwyVl9qa3ZDRGFnWEc3Q3Vtakk1dFkyUU5zakhNR05xUGxFQ2FQeXA2Q1hkVXJIMHpaeDExb3BFazhqbldrbzJtWWk1Q2J4UXpMeHh5aHZSM2hOX252TTEtcjJER2M5MDIxd3RGa1dCYW9XV0hBS1k5NkNrZ2x2d0NZM0p6MGtPRkRFb215ZlVENGxKR3hKc3BKZXI4ZGZqcG9UbEgyR1I4Nzh2SE1ycDJpOFE?oc=5","date":"2025-01-12","type":"deal","source":"prnewswire.com","summary":"Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - prnewswire.com","headline":"Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":3,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}